PF-04634817   Click here for help

GtoPdb Ligand ID: 9979

Synonyms: example 13 [US8293903] | PF-4634817 | PF04634817 | PF4634817
Immunopharmacology Ligand
Compound class: Synthetic organic
Comment: PF-04634817 is an oral dual CCR2/5 antagonist that was investigated for anti-inflammatory potential. The chemical structure of PF-04634817 is claimed (as example 13) in patent US8293903B2 [2].
Click here for help

Ligand Activity Visualisation Charts

These are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts.

✖

View interactive charts of activity data across species
2D Structure
Click here for help

2D Structure

An image of the ligand's 2D structure. For small molecules with SMILES these are drawn using the NCI/CADD Chemical Identifier Resolver. Click on the image to access the chemical structure search tool with the ligand pre-loaded in the structure editor. For other types of ligands, e.g. longer nucleotides and peptides, a manually drawn representation of the molecule may be provided.

✖
Click here for structure editor
Physico-chemical Properties
Click here for help

Physico-chemical Properties

Calculated molecular properties are available for small molecules and natural products (not peptides). Properties were generated using the CDK toolkit. All properties were selected to enable the prediction of the Lipinski Rule-of-Five profile or ‘druglikeness’ for each ligand. For more info on each category see the help pages.

✖
Hydrogen bond acceptors 8
Hydrogen bond donors 1
Rotatable bonds 8
Topological polar surface area 79.82
Molecular weight 511.28
XLogP 2.79
No. Lipinski's rules broken 0
SMILES / InChI / InChIKey
Click here for help

SMILES / InChI / InChIKey

SMILES (Simplified Molecular Input Line Entry Specification) A specification for unambiguously describing the structure of chemical molecules using short ASCII strings. Canonical SMILES specify a unique representation of the 2D structure without chiral or isotopic specifications. Isomeric SMILES include chiral specification and isotopes.

Standard InChI (IUPAC International Chemical Identifier) and InChIKey InChI is a non-proprietary, standard, textual identifier for chemical substances designed to facilitate linking of information and database searching. An InChIKey is a simplified version of a full InChI, designed for easier web searching.

✖
Canonical SMILES COC1COCCC1NC1CCC(C1)(C(C)C)C(=O)N1CC2CC1CN2c1ncnc(c1)C(F)(F)F
Isomeric SMILES CO[C@@H]1COCC[C@@H]1N[C@@H]1CC[C@](C1)(C(C)C)C(=O)N1C[C@@H]2C[C@H]1CN2c1ncnc(c1)C(F)(F)F
InChI InChI=1S/C25H36F3N5O3/c1-15(2)24(6-4-16(10-24)31-19-5-7-36-13-20(19)35-3)23(34)33-12-17-8-18(33)11-32(17)22-9-21(25(26,27)28)29-14-30-22/h9,14-20,31H,4-8,10-13H2,1-3H3/t16-,17+,18+,19+,20-,24+/m1/s1
InChI Key MCRWZBYTLVCCJJ-DKALBXGISA-N
No information available.
Summary of Clinical Use Click here for help
In a Phase 2 study (NCT01994291) in patients with diabetic macular edema, PF-04634817 was found to be inferior to monthly intravitreal ranibizumab (an anti-VEGFA biological drug) exposure [1]. This study was subsequently terminated for business reasons. A Phase 2 trial to evaluate efficacy of PF-04634817 as a treatment for diabetic nephropathy has also been completed (NCT01712061)
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT01712061 A Phase 2 Multi-Center Study To Evaluate The Efficacy And Safety Of A Chemokine CCR2/5 Receptor Antagonist In Adults With Type 2 Diabetes And Overt Nephropathy Phase 2 Interventional Pfizer
NCT01994291 A Phase 2, Multi-Center Study To Compare The Efficacy And Safety Of A Chemokine CCR2/5 Receptor Antagonist With Ranibizumab In Adults With Diabetic Macular Edema Phase 2 Interventional Pfizer